ClinicalTrials.gg
CompletedNCT00853307Updated Apr 8, 2022Results posted

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

A Phase 2 interventional study of Alisertib in Ovarian Carcinoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Ovarian Neoplasms by Takeda — none open to participants now, 1 under way, none of them phase 3. Ovarian Neoplasms · Takeda.

Started
2009
the only one that year
Phase 2
5 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Ovarian Neoplasms by Takeda, this one is the only one that started in 2009, is one of 5 in phase 2, and was the 3rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 11 studies in Ovarian Neoplasms by Takeda is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Ovarian Neoplasms by Takeda as a file.
02

Study summary

The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomas.

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. This study looked at the antitumor activity by response rate who would take alisertib.

The study enrolled 31 patients. Participants were categorized as per the disease state into 2 categories, refractory and resistant. Participants received:

  • Alisertib 50 mg

All participants took alisertib 50 mg capsules every 12 hours each day for 7 days followed by a 14-day rest period in a 21-day cycle (up to 26 cycles).

This multi-center trial was conducted in France, Poland and the United States. The overall time to participate in this study was 12 months, unless it is determined that a participant would benefit from continued therapy beyond 12 months. Participants made multiple visits to the clinic, and were contacted up to a maximum of every 12 weeks up to 12 months after last dose of study drug for follow-up assessments.

03

Conditions studied

  • Ovarian Carcinoma

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants 18 years or older.
  2. or cytologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  3. (ECOG) performance status 0 or 1.
  4. at least 1 year, OR

    • Surgically sterile, OR
    • If , agree to 2 effective methods of nonhormonal , or agree to completely abstain from heterosexual intercourse.
  5. Able to provide written .
  6. Within 7 days before study:

    • Absolute neutrophils (ANC) ≥ 1,500/μL
    • ≥100,000/ μL
    • Total must be \< 1.5 times (ULN)
    • (ALT) or aspartate aminotransferase (AST) must be ≤ 2.5 times the ULN. AST and ALT may be elevated up to 5 times the ULN if ascribed to liver disease.
    • ≥ 30 mL/minute
  7. Platinum- or -resistant disease.
  8. by (RECIST) OR Cancer antigen (CA) 125 level of > 40 units/mL AND clinical evidence disease.
  9. Recovered from effects of prior therapy.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating.
  2. Serious illness that could interfere with protocol completion.
  3. treatment 28 days prior to first dose.
  4. Maximum 4 prior systemic therapies: 2 platinum-based, 1 nonplatinum cytotoxic, 1 biological.
  5. Known Central Nervous System .
  6. Prior allogeneic bone marrow or organ transplantation.
  7. Radiotherapy within 21 days prior to first dose.
  8. Radiotherapy to > 25% bone marrow.
  9. Major surgery or infection requiring systemic antibiotic therapy within 14 days prior to first dose.
  10. Inability to swallow orally administered medication.
  11. Diagnosis or treatment of another within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected.
  12. Known history of (HIV) infection, , or .
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Alisertib 50 mg

    Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).

    Drug: Alisertib

Interventions

  • Alisertib capsules

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Combined Best Overall Response Rate Based on Investigator Assessment

    Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).

    Time frame: Every 2 cycles up to 12 months until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU)-every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time in days from the date of first study drug administration to the date of first documented Progressive Disease (PD) or death. PD is defined as 20% increase in the sum of the longest diameter of target lesions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125. For a participant who has not progressed and has not died, PFS is censored at the last response assessment that is stable disease (SD) or better.

    Time frame: Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

  2. Duration Of Response (DOR)

    DOR is defined as the time from the date of first documentation of a confirmed response to the date of first documented PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.

    Time frame: Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

  3. Time To Progression (TTP)

    TTP is defined as the time in days from the date of first study drug administration to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.

    Time frame: Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

  4. Clinical Benefit Rate

    Clinical benefit rate is defined as the percentage of participants with response and stable disease (SD), where in order for SD to qualify as having clinical benefit, there must be no progression of neoplastic disease for at least 4 treatment cycles.

    Time frame: Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

  5. Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose to 30 days past last dose (Up to 18.9 Months)

  6. Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events

    Vital signs included blood pressure, pulse rate, and oral temperature collected throughout the study. . A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Baseline, Cycle 1 Days 8 and 15, then Day 1 of every cycle (21 days), End of Treatment, End of Study/FU every 12 weeks for up to 12 months (Up to 22 Months)

  7. Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events

    Laboratory tests included Hematology and Chemistry. Abnormal laboratory value were assessed as an AE if the value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Baseline, Cycle 1 Days 8 and 15, then Every cycle Days 1, 8 and 15 to End of Treatment Up to 18.0 Months

07

Results

Posted Mar 27, 2018

Participant flow

Participants took part in the study at 17 investigative sites in France, Poland and the United States from 23 March 2009 to 27 January 2011.

Participant flow — Overall Study
MilestoneAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
Started625
Completed420
Not completed25
Withdrew: Adverse event12
Withdrew: Withdrawal by subject12
Withdrew: Reason not specified01

Outcome measures

PrimaryCombined Best Overall Response Rate Based on Investigator Assessment

Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).

Time frame:
Every 2 cycles up to 12 months until progressive disease (PD); Participants who discontinue study drug before PD: Follow-Up (FU)-every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)
Reported as:
Number · percentage of participants
Combined Best Overall Response Rate Based on Investigator Assessment
percentage of participantsAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
Combined Best Overall Response Rate Based on Investigator Assessment012
SecondaryProgression Free Survival (PFS)

PFS is defined as the time in days from the date of first study drug administration to the date of first documented Progressive Disease (PD) or death. PD is defined as 20% increase in the sum of the longest diameter of target lesions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125. For a participant who has not progressed and has not died, PFS is censored at the last response assessment that is stable disease (SD) or better.

Time frame:
Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)
Reported as:
Median · days
Progression Free Survival (PFS)
daysAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
Progression Free Survival (PFS)36.5 (23.0 to 120.0)77.0 (43.0 to 122.0)
SecondaryDuration Of Response (DOR)

DOR is defined as the time from the date of first documentation of a confirmed response to the date of first documented PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.

Time frame:
Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

No measurements were reported for this outcome.

SecondaryTime To Progression (TTP)

TTP is defined as the time in days from the date of first study drug administration to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions.

Time frame:
Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)

No measurements were reported for this outcome.

SecondaryClinical Benefit Rate

Clinical benefit rate is defined as the percentage of participants with response and stable disease (SD), where in order for SD to qualify as having clinical benefit, there must be no progression of neoplastic disease for at least 4 treatment cycles.

Time frame:
Every 2 cycles up to 12 months until PD; Participants who discontinue study drug before PD: FU - every 12 weeks up to 12 months until PD/other cancer therapy; CA 125 Day 1 of cycle, End of Treatment and FU (Up to 22 Months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate
percentage of participantsAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
Clinical Benefit Rate032
SecondaryNumber of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose to 30 days past last dose (Up to 18.9 Months)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
participantsAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
AE624
SAE47
SecondaryNumber of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events

Vital signs included blood pressure, pulse rate, and oral temperature collected throughout the study. . A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Baseline, Cycle 1 Days 8 and 15, then Day 1 of every cycle (21 days), End of Treatment, End of Study/FU every 12 weeks for up to 12 months (Up to 22 Months)
Reported as:
Number · participants
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events
participantsAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
Pyrexia26
Dyspnoea04
Weight decreased03
Tachycardia02
Hypertension02
Dyspnoea exertional01
Bradycardia01
Shock10
SecondaryNumber of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events

Laboratory tests included Hematology and Chemistry. Abnormal laboratory value were assessed as an AE if the value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Baseline, Cycle 1 Days 8 and 15, then Every cycle Days 1, 8 and 15 to End of Treatment Up to 18.0 Months
Reported as:
Number · participants
Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events
participantsAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
Neutropenia317
Anaemia214
Leukopenia111
Thrombocytopenia18
Dehydration17
Hypokalaemia24
Alanine aminotransferase increased06
Aspartate aminotransferase increased06
Hyperglycaemia14
Hypomagnesaemia14
Blood alkaline phosphatase increased14
Febrile neutropenia03
Hyponatraemia12
Haemoglobin decreased12
Granulocytopenia02
Neutrophil count increased02
White blood cell count increased02
Hyperbilirubinaemia11
Lymphopenia10
Hyperkalaemia01
Hypernatraemia01
Hypercholesterolaemia01
Transaminases increased10
Granulocyte count decreased01
Blood calcium increased01
Blood magnesium decreased01
Platelet count decreased10
Blood albumin decreased01
Creatinine renal clearance decreased01
Hypoxia01
Bacteraemia10

Adverse events

Collected over First dose of study drug to 30 past last dose of study drug (Up to18.9 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib 50 mg (Platinum-Refractory)—4/6 (66.7%)6/6 (100%)
Alisertib 50 mg (Platinum-Resistant)—7/25 (28%)24/25 (96%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
StomatitisGastrointestinal disorders1/61/25
Abdominal painGastrointestinal disorders1/61/25
Small intestinal obstructionGastrointestinal disorders1/61/25
Intestinal obstructionGastrointestinal disorders1/60/25
VomitingGastrointestinal disorders1/60/25
NeutropeniaBlood and lymphatic system disorders1/61/25
AnaemiaBlood and lymphatic system disorders1/61/25
LeukopeniaBlood and lymphatic system disorders1/61/25
PyrexiaGeneral disorders1/62/25
BacteraemiaInfections and infestations1/60/25
Most frequent other events
Showing 10 of 77
Most frequent other events
EventAlisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)
VomitingGastrointestinal disorders4/68/25
NeutropeniaBlood and lymphatic system disorders3/616/25
FatigueGeneral disorders3/615/25
DiarrhoeaGastrointestinal disorders3/614/25
AlopeciaSkin and subcutaneous tissue disorders1/614/25
StomatitisGastrointestinal disorders2/613/25
AnaemiaBlood and lymphatic system disorders1/613/25
NauseaGastrointestinal disorders3/611/25
LeukopeniaBlood and lymphatic system disorders1/611/25
Abdominal painGastrointestinal disorders2/68/25

Baseline characteristics

Safety Population is defined as all participants who receive any amount of alisertib.

Age, Continuous
Age, Continuous(years)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
Mean58.3 ± 15.3856.6 ± 14.1957.0 ± 14.18
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
Female62531
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
White62430
Asian011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
Hispanic or Latino112
Not Hispanic or Latino32225
Not Reported224
Primary diagnosis
Primary diagnosis(participants)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
Epithelial Ovarian52025
Fallopian Tube011
Primary Peritoneal Carcinoma145
Years Since Initial Diagnosis
Years Since Initial Diagnosis(years)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
Mean1.59 ± 0.7362.26 ± 1.4482.13 ± 1.356
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
ECOG Performance Status = 021820
ECOG Performance Status = 14711
Height
Height(centimeter (cm))Alisertib 50 mg (Platinum-Refractory)Alisertib 50 mg (Platinum-Resistant)Total
Mean162.0 ± 4.83160.9 ± 7.76161.0 ± 7.34

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Summit Medical Group
    Berkeley Heights, New Jersey 07922, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2009 to primary completion in Nov 2009, 8 months.

Results were first posted in Mar 2018, 8 years 4 months after primary completion. A results delay was requested in Jan 2012.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 8 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2009
First posted
Mar 2, 2009
StartActual
Mar 23, 2009
Primary completionActual
Nov 23, 2009
CompletionActual
Jan 27, 2011
Results delay requested
Jan 27, 2012
Results first posted
Mar 27, 2018
Last update
Apr 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00853307
Responsible party
Sponsor
First posted
Mar 2, 2009
Start date
Mar 23, 2009
Primary completion
Nov 23, 2009
Completion
Jan 27, 2011
Results posted
Mar 27, 2018
Last update
Apr 8, 2022

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion